Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.57 |
| ▸ | HTR3A | P46098 | 12/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | HRH2 | P25021 | 2/20 | 0.55 |
| ▸ | HTR1B | P28222 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | HTR5A | P47898 | 2/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475022 | 0.89 | HAO1 (0.55) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL76793 | 0.89 | HAO1 (0.55) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL9487702 | 0.87 | MAPT (0.48) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL16768825 | 0.87 | HTR1A (0.45) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL11225501 | 0.85 | HTR1A (0.59) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL10079070 | 0.84 | HTR1A (0.51) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL14723181 | 0.84 | SLC6A4 (0.57) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL16268913 | 0.84 | HTR1A (0.51) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL16269571 | 0.84 | AR (0.51) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 | |
| SCHEMBL17156541 | 0.84 | HTR1A (0.51) | HTR1AHTR3ASLC6A4CYP1A2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030008-A1 | PROCESS FOR THE PREPARATION OF VORTIOXETINE | LUPIN LIMITED (IN) | 2018-02-01 | — | — | US | disclosed |
| US-9861630-B1 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | H. LUNDBECK A/S (DK) | 2018-01-09 | — | — | US | disclosed |
| US-20170360777-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H. LUNDBECK A/S (DK) | 2017-12-21 | — | — | US | disclosed |
| WO-2017162536-A1 | VORTIOXETINE PRODRUGS | H. LUNDBECK A/S (DK) | 2017-09-28 | — | — | WO | disclosed |
| US-9493409-B2 | Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine | LEK PHARMACEUTICALS D.D. (SI) | 2016-11-15 | — | — | US | disclosed |
| US-20160083359-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | LUNDBECK & CO AS H (DK) | 2016-03-24 | — | — | US | disclosed |
| US-20160060215-A1 | New Process For The Synthesis Of 1-(2-((2,4-Dimethylphenyl)Thio)Phenyl)Piperazine | LEK PHARMACEUTICALS D.D. (SI) | 2016-03-03 | — | — | US | disclosed |
| US-9227946-B2 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | H. LUNDBECK A/S (DK) | 2016-01-05 | — | — | US | disclosed |
| US-9227946-B2 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | H. LUNDBECK A/S (DK) | 2016-01-05 | — | — | US | disclosed |
| US-9125908-B2 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | H. LUNDBECK A/S (DK) | 2015-09-08 | — | — | US | disclosed |
| US-20150005318-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | LUNDBECK & CO AS H (DK) | 2015-01-01 | — | — | US | disclosed |
| US-20140377363-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | LUNDBECK & CO AS H (DK) | 2014-12-25 | — | — | US | disclosed |
| US-20140371453-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | LUNDBECK & CO AS H (DK) | 2014-12-18 | — | — | US | disclosed |
| US-20140315921-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | LUNDBECK & CO AS H (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140256943-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | H. LUNDBECK A/S (DK) | 2014-09-11 | — | — | US | disclosed |
| US-20140248356-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | H. LUNDBECK A/S (DK) | 2014-09-04 | — | — | US | disclosed |
| US-20140248355-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | H. LUNDBECK A/S (DK) | 2014-09-04 | — | — | US | disclosed |
| US-20140248355-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | H. LUNDBECK A/S (DK) | 2014-09-04 | — | — | US | disclosed |
| US-8722684-B2 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | H. LUNDBECK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| US-20100297240-A1 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H. LUNDBECK A/S (DK) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297240-A1 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20140315921-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | HTR2C, HTR5A, HTR2A | HTR1A 5/4885HTR3A 4/4885SLC6A4 16/4885 |
| US-20170360777-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | HTR3A, HTR2C, HTR2A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20140371453-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | HTR2C, HTR5A, HTR2A | HTR1A 5/4885HTR3A 4/4885SLC6A4 18/4885 |
| US-20140377363-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | HTR2C, HTR3A, HTR5A | HTR1A 7/4885HTR3A 2/4885SLC6A4 17/4885 |
| US-20140248356-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20160083359-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20150005318-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | HTR2C, HTR3A, HTR2A | HTR1A 6/4885HTR3A 2/4885SLC6A4 9/4885 |
| US-20140248355-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20180030008-A1 | PROCESS FOR THE PREPARATION OF VORTIOXETINE | SLC6A4, SLC6A2, PDE8B | HTR1A 51/4885HTR3A 74/4885SLC6A4 1/4885 |
| US-20160060215-A1 | New Process For The Synthesis Of 1-(2-((2,4-Dimethylphenyl)Thio)Phenyl)Piperazine | HTR5A, HTR2A, HTR2C | HTR1A 4/4885HTR3A 9/4885SLC6A4 7/4885 |
| US-20140256943-A1 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.